Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down

Social Media in the Pharmaceutical Industry
Bookmark and Share

Astra Zeneca

Two primary themes are captured in the paper:

1. Social media is a fundamental part of advancing public health.

2. Pharmaceutical companies have a responsibility to engage more fully in social media.

The paper includes the thoughts of patients, health advocates, former government officials, bloggers and others who participated in a roundtable discussion that AstraZeneca convened late last year. The discussion, which was facilitated by members of Google’s Health Industry Team, sought specific feedback on AstraZeneca’s social media principles – and included considerable discussion on the social media guidelines expected to be released by the FDA later this year.

It summarises and addresses key discussion points that arose from both the Social Media Roundtable and DPE, as well as several considerations for the FDA in its development of social media guidance.

In the paper, Astrazeneca put forth five principles required for appropriate pharmaceutical manufacturer engagement in social media.

The white paper says the FDA should engage with the pharmaceutical industry to help them research and resolve issues raised by social media.

Further Information

Related Content

30 to 40 % of Mental Illnesses in UAE are Schizophrenia-related
Catatonic schizophrenia disappeared from the UAE thanks to the country’s advanced healthcare practices
Thursday, October 29, 2009
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!